Global Anticoagulant Reversal Drugs Market: Overview

Increase in the cases of atrial fibrillation and rise in the number of older population are some of the key factors that are expected to create revenue-generating opportunities in the global anticoagulant reversal drugs market. Thus, the market is estimated to expand at a CAGR of 15.6% during the forecast period from 2018 to 2026 and gain the valuation of US$ 2,085.1 Mn by 2026.

The study by Transparency Market Research (TMR) gives 360-degree analysis of major factors influencing the growth curve of the global anticoagulant reversal drugs market. Thus, readers are enlightened on many important factors such growth opportunities, growth drivers, restraints, challenges, historical and present trends, and competition landscape of the market for global anticoagulant reversal drugs.

The analysts of the report by TMR have performed the segmentation of the global anticoagulant reversal drugs market based on several crucial parameters such as distribution channel, product, and region. On the basis of distribution channel, the global anticoagulant reversal drugs market is divided into three segments, namely, retail pharmacies, hospital pharmacies, and others. Based on product, the segmentation of the global market is performed into many parts such as vitamin K, prothrombin complex concentrates, tranexamic acid, protamine, AndeXXa, idarucizumab, and others.

Increasing Prevalence of Cardiac Disorders Fuels Sales Growth in Anticoagulant Reversal Drugs Market

The market is estimated to be driven by rise in the number of people suffering from cardiac disorders. Furthermore, increase in cases of gastrointestinal hemorrhage and intracranial hemorrhage is creating high demand for anticoagulant reversal drugs across the globe. Moreover, surge in the cases of warfarin therapy that need reversal of anticoagulants is fueling the expansion of the market.

In recent years, there is considerable growth in the use of vitamin K in the reversal of warfarin anticoagulation therapy. This factor is boosting the sales prospects in the anticoagulant reversal drugs industry. Furthermore, the market is being driven by several key factors such as increase in focus of players on launching precise drugs intended for reversal of the action of anticoagulants, new technology add-on status (NTAP) provided to specific drugs, and unfulfilled clinical requirements owing to absence of specific drugs for anticoagulant reversal.

Players operating in the anticoagulant reversal drugs market are increasing inclination toward providing their products to hospital pharmacies as compared to other distribution channels. As a result, the hospital pharmacies segment is expected to maintain its dominating position in the forecast period.

North America to Maintain Leading Position in Anticoagulant Reversal Drugs Industry in Forecast Period

The global anticoagulant reversal drugs market shows presence in many geographical regions including Europe, North America, Latin America, Middle East & Africa, and Asia Pacific. Of them, Europe and North America collectively hold share of over 77% of the global anticoagulant reversal drugs market.

The anticoagulant reversal drugs market in North America is estimated to maintain its dominating position in the forecast period owing to several favorable factors such as increase in new product launches, presence of highly advanced healthcare infrastructure, approval of AndeXXa, and rising focus of regional market players on R&D projects.

anticoagulant reversal drugs market

Increasing Focus of Enterprises on New Product Launches to Shape Market Expansion

The global anticoagulant reversal drugs market is fragmented in nature. Presence of many small as well as established companies represents the intense competition level in the market. Thus to sustain in this competition, players are using different strategic moves such as mergers, acquisitions, partnerships, and joint ventures. These activities are helping companies to expand their businesses in emerging regions. Furthermore, industry leaders are concentrating on new product launches. These efforts are fueling the growth of the global anticoagulant reversal drugs market.

Some important companies operating in the anticoagulant reversal drugs market include Pfizer, Inc., Bausch Health Companies, Inc., Amneal Pharmaceuticals, Inc., Fresenius Kabi AG, CSL Limited, Boehringer Ingelheim GmbH, Perosphere Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., and Octapharma AG.

The global anticoagulant reversal drugs market has been segmented as follows:

Product

  • Prothrombin Complex Concentrates (PCC)
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
  • Others

Distribution Channel

 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Region

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe 
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America 
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa

Frequently Asked Questions

The global anticoagulant reversal drugs market was worth US$ 607.3 Mn and is projected to reach a value of US$ 2,085.1 Mn by the end of 2026

Anticoagulant reversal drugs market is anticipated to grow at a CAGR of 15.6% during the forecast period

North America accounted for a major share of the global anticoagulant reversal drugs market

Anticoagulant reversal drugs market is driven by increase in focus of players on launching precise drugs intended for reversal of the action of anticoagulants, and unfulfilled clinical requirements owing to absence of specific drugs for anticoagulant reversal

Key players in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Acronyms Used

3. Research Methodology

4. Executive Summary

5. Market Overview
     5.1. Product Overview
     5.2. Market Dynamics
           5.2.1. Drivers
                     5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population 
                     5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages
                     5.2.1.3. NTAP status for specific drugs
           5.2.2. Restraints
                     5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs 
                     5.2.2.2. Risk associated with reversing anticoagulation 
           5.2.3. Opportunities
                     5.2.3.1. Unmet clinical needs
                     5.2.3.2.  Untapped market in emerging economies 
           5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016?2026
           5.2.5. Global Anticoagulant Reversal Drugs Market Outlook
           5.2.6. Key Industry Developments
           5.2.7. Regulatory Scenario
           5.2.8. Reimbursement Scenario
           5.2.9. Pipeline Analysis
           5.2.10. Healthcare Overview 

6. Global Anticoagulant Reversal Drugs Market Analysis, by Product 
     6.1. Introduction
     6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product 
     6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016?2026
           6.3.1. Prothrombin Complex Concentrates (PCC)
           6.3.2. Vitamin K
           6.3.3. Protamine
           6.3.4. Tranexmic Acid
           6.3.5. Idarucizumab
           6.3.6. Andexxa
           6.3.7. Others
     6.4. Market Attractiveness, by Product 

7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel
     7.1. Introduction
     7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel
     7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           7.3.1. Hospital Pharmacies
           7.3.2. Retail Pharmacies 
           7.3.3. Others
     7.4. Market Attractiveness, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis, by Region
     8.1. Introduction
     8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region
           8.2.1. North America
           8.2.2. Europe
           8.2.3. Asia Pacific 
           8.2.4. Latin America 
           8.2.5. Middle East & Africa
     8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis
     9.1. Key Findings
     9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016?2026
           9.2.1. U.S.
           9.2.2. Canada
     9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
           9.3.1. Prothrombin Complex Concentrates (PCC)
           9.3.2. Vitamin K
           9.3.3. Protamine
           9.3.4. Tranexmic Acid
           9.3.5. Idarucizumab
           9.3.6. Andexxa
           9.3.7. Others
     9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           9.4.1. Hospital Pharmacies
           9.4.2. Retail Pharmacies 
           9.4.3. Others
     9.5. North America Market Attractiveness Analysis
           9.5.1. By Country
           9.5.2. By Product 
           9.5.3. By Distribution Channel

10. Europe Anticoagulant Reversal Drugs Market Analysis
     10.1. Key Findings
     10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
           10.2.1. U.K.
           10.2.2. Germany
           10.2.3. France
           10.2.4. Italy
           10.2.5. Spain
           10.2.6. Rest of Europe
     10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
           10.3.1. Prothrombin Complex Concentrates (PCC)
           10.3.2. Vitamin K
           10.3.3. Protamine
           10.3.4. Tranexmic Acid
           10.3.5. Idarucizumab
           10.3.6. Andexxa
           10.3.7. Others
     10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           10.4.1. Hospital Pharmacies
           10.4.2. Retail Pharmacies 
           10.4.3. Others
     10.5. Europe Market Attractiveness Analysis
           10.5.1. By Country/Sub-region
           10.5.2. By Product 
           10.5.3. By Distribution Channel

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis
     11.1. Key Findings
     11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
           11.2.1. China
           11.2.2. Japan
           11.2.3. India
           11.2.4. Australia
           11.2.5. Rest of Asia Pacific 
     11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
           11.3.1. Prothrombin Complex Concentrates (PCC)
           11.3.2. Vitamin K
           11.3.3. Protamine
           11.3.4. Tranexmic Acid
           11.3.5. Idarucizumab
           11.3.6. Andexxa
           11.3.7. Others
     11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           11.4.1. Hospital Pharmacies
           11.4.2. Retail Pharmacies 
           11.4.3. Others
     11.5. Asia Pacific Market Attractiveness Analysis
           11.5.1. By Country/Sub-region
           11.5.2. By Product 
           11.5.3. By Distribution Channel

12. Latin America Anticoagulant Reversal Drugs Market Analysis
     12.1. Key Findings
     12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
           12.2.1. Brazil 
           12.2.2. Mexico
           12.2.3. Rest of Latin America
     12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
           12.3.1. Prothrombin Complex Concentrates (PCC)
           12.3.2. Vitamin K
           12.3.3. Protamine
           12.3.4. Tranexmic Acid
           12.3.5. Idarucizumab
           12.3.6. Andexxa
           12.3.7. Others
     12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           12.4.1. Hospital Pharmacies
           12.4.2. Retail Pharmacies 
           12.4.3. Others
     12.5. Latin America Market Attractiveness Analysis
           12.5.1. By Country/Sub-region
           12.5.2. By Product 
           12.5.3. By Distribution Channel

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis
     13.1. Key Findings
     13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
           13.2.1. GCC Countries 
           13.2.2. South Africa            
           13.2.3. Israel            
           13.2.4. Rest of Middle East & Africa
     13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
           13.3.1. Prothrombin Complex Concentrates (PCC)
           13.3.2. Vitamin K
           13.3.3. Protamine
           13.3.4. Tranexmic Acid
           13.3.5. Idarucizumab
           13.3.6. Andexxa
           13.3.7. Others
     13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
           13.4.1. Hospital Pharmacies
           13.4.2. Retail Pharmacies 
           13.4.3. Others
     13.5. Middle East & Africa Market Attractiveness Analysis
           13.5.1. By Country/Sub-region
           13.5.2. By Product 
           13.5.3. By Distribution Channel

14. Competitive Landscape
     14.1. Competition Matrix
     14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
     14.3. Company Profiles
           14.3.1. Bausch Health Companies, Inc. 
                     14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.1.2. Financial Overview 
                     14.3.1.3. Product Portfolio
                     14.3.1.4. SWOT Analysis
                     14.3.1.5. Strategic Overview
           14.3.2. Pfizer, Inc. 
                     14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.2.2. Financial Overview 
                     14.3.2.3. Product Portfolio
                     14.3.2.4. SWOT Analysis
           14.3.3. Fresenius Kabi AG 
                     14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.3.2. Financial Overview 
                     14.3.3.3. Product Portfolio
                     14.3.3.4. SWOT Analysis
           14.3.4. Amneal Pharmaceuticals, Inc. 
                     14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.4.2. Product Portfolio
                     14.3.4.3. SWOT Analysis
                     14.3.4.4. Strategic Overview
           14.3.5. Boehringer Ingelheim GmbH 
                     14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.5.2. Financial Overview 
                     14.3.5.3. Product Portfolio
                     14.3.5.4. SWOT Analysis
                     14.3.5.5. Strategic Overview
           14.3.6. CSL Limited 
                     14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.6.2. Financial Overview 
                     14.3.6.3. Product Portfolio
                     14.3.6.4. SWOT Analysis
           14.3.7. Octapharma AG 
                     14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.7.2. Financial Overview 
                     14.3.7.3. Product Portfolio
                     14.3.7.4. SWOT Analysis
           14.3.8. Portola Pharmaceuticals, Inc.
                     14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.8.2. Financial Overview 
                     14.3.8.3. Product Portfolio
                     14.3.8.4. SWOT Analysis
                     14.3.8.5. Strategic Overview
           14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)
                     14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                     14.3.9.2. Product Portfolio
                     14.3.9.3. SWOT Analysis

List of Tables

Table 01: Reimbursement Scenario for AndeXXa
Table 02: Reimbursement Scenario for Praxbind
Table 03: Reimbursement Scenario for Kcentra
Table 04: Pipeline Analysis
Table 05: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 06: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 10: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 11: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 13: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 16: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 19: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 22: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures 

Figure 01: Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2018–2026
Figure 03: Market Value Share, by Product (2018)
Figure 04: Market Value Share, by Distribution Channel (2018)
Figure 05: Market Value Share, by Region (2018)
Figure 06: Regulatory Approval Process - U.S. 
Figure 07: Regulatory Approval Process - Europe 
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2016–2026
Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2016–2026
Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2016–2026
Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2016–2026
Figure 14: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 15: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2016–2026
Figure 16: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2016–2026
Figure 17: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 18: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 19: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 20: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 21: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 22: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 23: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2017 and 2026 
Figure 24: Global Anticoagulant Reversal Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2017 and 2026
Figure 27: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2018-2026
Figure 28: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 29: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 30: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 31: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
Figure 61: Product Overview - Bausch Health Companies, Inc.
Figure 62: Breakdown of Net Sales (%), by Region, 2017 - Bausch Health Companies, Inc.
Figure 63: Revenue (US$ Mn), 2015–2017 - Bausch Health Companies, Inc.
Figure 64: R&D Expenses (US$ Mn), 2015-2017 - Bausch Health Companies, Inc.
Figure 65: Product Overview - Pfizer, Inc.
Figure 66: Breakdown of Net Sales, by Region, 2017 - Pfizer, Inc.
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017 - Pfizer, Inc.
Figure 68: R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017 - Pfizer, Inc.
Figure 69: Product Overview - Fresenius Kabi AG
Figure 70: Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017 - Fresenius Kabi AG 
Figure 71: Breakdown of Net Sales, by Region, 2017 - Fresenius Kabi AG
Figure 72: Breakdown of Net Sales, by Segment, 2017 - Fresenius Kabi AG 
Figure 73: Research & Development Cost, 2016 - 2017 (US$ Mn) - Fresenius Kabi AG 
Figure 74: Product Overview - Amneal Pharmaceuticals, Inc.
Figure 75: Product Overview - Boehringer Ingelheim GmbH
Figure 76: Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017 - Boehringer Ingelheim GmbH 
Figure 77: Breakdown of Net Sales, by Business and Business Segment Level, 2017 - Boehringer Ingelheim GmbH 
Figure 78: Breakdown of Net Sales, by Region (Company Level), 2017 - Boehringer Ingelheim GmbH 
Figure 79: R&D Expenditure (US$ Bn), 2013–2017 - Boehringer Ingelheim GmbH 
Figure 80: Product Overview: CSL Limited
Figure 81: Total Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 – CSL Limited
Figure 82: R&D Investment, (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 83: Sales Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 84: Net Profit (US$ Mn), 2016–2018 - CSL Limited
Figure 85: Product Overview - Octapharma AG
Figure 86: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Octapharma AG 
Figure 87: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Octapharma AG 
Figure 88: Year-end Employee Headcount and Y-o-Y Growth, 2015-2017 - Octapharma AG 
Figure 89: Gross profit (US$ Mn) and Y-o-Y Growth, 2016–2017 - Octapharma AG 
Figure 90: Product Overview - Portola Pharmaceuticals, Inc.
Figure 91: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Portola Pharmaceuticals, Inc. 
Figure 92: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Portola Pharmaceuticals, Inc. 
Figure 93: Product Overview - Perosphere Pharmaceuticals Inc.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Anticoagulant Reversal Drugs Market